Active substance
Incobotulinumtoxina
- US FDA 1
- Health Canada 3
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| Xeomin | 50 UNITS/VIAL; 100 UNITS/VIAL; 200 UNITS/VIAL | injectable · injection | MERZ PHARMS | Prescription | 30 Jul 2010 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| XEOMIN | 02324032 | 100 UNIT / VIAL | POWDER FOR SOLUTION · INTRAGLANDULAR; INTRAMUSCULAR | MERZ PHARMACEUTICALS GMBH |
| XEOMIN | 02371081 | 50 UNIT / VIAL | POWDER FOR SOLUTION · INTRAGLANDULAR; INTRAMUSCULAR | MERZ PHARMACEUTICALS GMBH |
| XEOMIN COSMETIC | 02383489 | 100 UNIT / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR | MERZ PHARMACEUTICALS GMBH |
Safety signals and safety-related labeling changes
- US FDA 25 Jun 2026 Xeomin — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.